Alendronate

Routes
Oral (PO)
Half-Life (t½)
PO: 10d
Formula
C4H13NO7P2
Molecular Weight
249.1 g/mol
PubChem CID
2088
Aliases
Fosamax

Pharmacological Mechanism

Aminobisphosphonate — incorporates into hydroxyapatite + inhibits farnesyl pyrophosphate synthase in osteoclasts → osteoclast apoptosis → reduced bone resorption. First-line oral therapy for postmenopausal osteoporosis. Esophageal irritation requires upright positioning + 30 min fast post-dose.

Half-Life & Elimination Curve (PO: 10d)

100%50%25%12.5%0%0h0×t½10d1×t½20d2×t½30d3×t½40d4×t½50d5×t½0×t½ (0h): 100% remaining (~17 µg/L)1×t½ (10d): 50% remaining (~8.49 µg/L)2×t½ (20d): 25% remaining (~4.25 µg/L)3×t½ (30d): 12.5% remaining (~2.12 µg/L)4×t½ (40d): 6.3% remaining (~1.06 µg/L)5×t½ (50d): 3.1% remaining (~0.531 µg/L)
Plasma (PO)t½ Decay (10d)
  • 0×t½0h100% (17 µg/L)
  • 1×t½10d50% (8.49 µg/L)
  • 2×t½20d25% (4.25 µg/L)
  • 3×t½30d12.5% (2.12 µg/L)
  • 4×t½40d6.3% (1.06 µg/L)
  • 5×t½50d3.1% (0.531 µg/L)
Elimination t½10d (PO)
Rate Constant (ke)0.00289 h⁻¹
Time to Peak (Tmax)10.4h
Est. Peak (Cmax)17 µg/L
Clearance (CL)0.0809 L/h
97% Washout (5×t½)50d

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References